Adage Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Adage Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-70,000	Closed	-$791K	–	1101
2022 Q2	$791K	Sell	70,000 -120,000	-63%	-$2.41M	﹤0.01%	931
2022 Q1	$5.68M	Buy	190,000 +180,500	+1,900%	+$4.89M	0.01%	814
2021 Q4	$252K	Buy	+9,500	New	+$287K	﹤0.01%	976
2014 Q4	–	Sell	-60,000	Closed	-$1.16M	–	759
2014 Q3	$1.16M	Hold	60,000	–	–	﹤0.01%	688
2014 Q2	$2.18M	Sell	60,000 -40,000	-40%	-$1.36M	0.01%	653
2014 Q1	$3.88M	Buy	+100,000	New	+$3.56M	0.01%	612

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners's RIGL Position: Q3 2022 in Review

Adage Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 70,000 shares — an estimated $791K sold.

Adage Capital Partners first reported a position in RIGL in Q1 2014 and held it in 6 quarters. The position peaked at $5.68M in Q1 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

Adage Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Adage Capital Partners sold 70,000 Rigel Pharmaceuticals shares in Q3 2022, an estimated $791K.
Adage Capital Partners first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Adage Capital Partners's Rigel Pharmaceuticals position peaked at $5.68M in Q1 2022.
138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Adage Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.